FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola

Thursday, April 16, 2020 1 min read

Key Takeaway: FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola

Full Press Release Details

FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola.